Allergic rhinitis
Conditions
Interventions
Group A:The probiotic combination of animal bifidobacterium lactis subspecies Bb-12 + rhamnolipid cheese GG + rhamnolipid cheese HN001 + short bifidobacterium M-16V in combination with drug treatment
Group B:The conventional drug treatment group
Sponsors
Shanghai Children's Medical Center, Affiliated to Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
3 Years to 8 Years
Inclusion criteria
Inclusion criteria: Children with allergic rhinitis (AR) aged 3–8 years were enrolled, with AR diagnosed in accordance with the diagnostic criteria specified in the 2019 Revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines. The diagnostic criteria are as follows: 1. Symptoms: Presence of two or more of the following symptoms (watery rhinorrhea, nasal itching, nasal obstruction, and sneezing), with daily symptom duration of at least 1 hour (either continuously or cumulatively). Ocular symptoms such as ocular itching and conjunctival hyperemia may be accompanied. Severe cases may exhibit the allergic salute maneuver. 2. Signs: Common findings include pale and edematous nasal mucosa with watery nasal discharge. Severe cases may present with allergic shiners or allergic creases. 3. Laboratory evidence: In addition to the aforementioned clinical manifestations (symptoms and signs), serum-specific immunoglobulin E (sIgE) testing should confirm positivity for specific inhalant allergens (> 0.35 kU/mL).
Exclusion criteria
Exclusion criteria: 1. Comorbid with allergic asthma and atopic dermatitis; 2. Comorbid with chronic active urticaria; 3. Receiving immunosuppressive therapy; 4. Having undergone allergen-specific immunotherapy (AIT) within the past year; 5. Having used probiotics, prebiotics or antibiotics within the past 3 months; 6. Having received corticosteroid therapy for more than 1 week within the past 3 months; 7. Comorbid with autism, depression or obesity (BMI > 30); 8. Comorbid with severe primary diseases involving the heart, liver, kidneys, hematopoietic system or other vital organs; 9. The patient or their immediate family members suffering from immunodeficiency or autoimmune diseases (e.g., inflammatory bowel disease, ulcerative colitis, irritable bowel syndrome, etc.); 10. Having constipation or diarrhea lasting for >=6 months.Additionally, children with severe immunodeficiency or acute exacerbation of chronic diseases were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Analogue Scale (VAS);Rhinitis Control Assessment Test (RCAT); | — |
Secondary
| Measure | Time frame |
|---|---|
| Allergen Skin Prick Test (SPT) ;Serum-specific Immunoglobulin E (sIgE) Test; | — |
Countries
China
Contacts
Public ContactYoujin Li
Shanghai Children's Medical Center, Affiliated to Shanghai Jiao Tong University School of Medicine
Outcome results
None listed